|
Published online before print May 13, 2009, doi:10.1212/WNL.0b013e3181a8164c)
© 2009 American Academy of Neurology Cyclophosphamide therapy in pediatric multiple sclerosisFrom The Hospital for Sick Children (N.M., H.M.B., B.L.B.), University of Toronto, Canada; Partners Pediatric Multiple Sclerosis Center (M.P.G., T.C.), Massachusetts General Hospital for Children, Boston; Children's Hospital (M.P.G.), Boston; and Partners Multiple Sclerosis Center (L.S., T.C.), Brigham and Women's Hospital, Boston, MA. Address correspondence and reprint requests to Dr. Tanuja Chitnis, Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, ACC-708, 55 Fruit Street, Boston, MA 02114 tchitnis{at}partners.org. Objective: To review our multicenter experience with cyclophosphamide in the treatment of children with multiple sclerosis (MS). Methods: Retrospective chart review of children with MS treated with cyclophosphamide. Demographic, clinical, treatment, and MRI parameters were collected. Results: We identified 17 children with MS treated with cyclophosphamide. All but one had worsening of Expanded Disability Status Scale scores or multiple relapses prior to treatment initiation. Children were treated with one of three regimens: 1) induction therapy alone; 2) induction therapy with pulse maintenance therapy; or 3) pulse maintenance therapy alone. Treatment resulted in a reduction in relapse rate and stabilization of disability scores assessed 1 year after treatment initiation in the majority of patients. Longer follow-up was available for most cases. Cyclophosphamide was well tolerated in most patients. However, side effects included vomiting, transient alopecia, osteoporosis, and amenorrhea. One patient developed bladder carcinoma that was successfully treated. Conclusions: Cyclophosphamide is an option for the treatment of children with aggressive multiple sclerosis refractory to first-line therapies. Recommendations regarding patient selection, treatment administration, and monitoring are discussed.
Abbreviations: ARR = annualized relapse rates; EDSS = Expanded Disability Status Scale; IVIg = IV immunoglobulin; MS = multiple sclerosis; PLEX = plasmapheresis; RRMS = relapsing remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis.
e-Pub ahead of print on May 13, 2009, at www.neurology.org. Supported by the Pediatric Multiple Sclerosis Centers of Excellence Grant from the National Multiple Sclerosis Society, USA (T.C.), and by the Multiple Sclerosis Scientific Research Foundation of Canada (B.L.B.). M.P.G. is supported by a National Multiple Sclerosis Society (Central New England Chapter) Clinical Fellowship. Disclosure: The authors report no disclosures. Medications: Cyclophosphamide (CytoxanTM; BMS Oncology, Princeton, NJ). Received October 16, 2008. Accepted in final form February 9, 2009.
Related Article
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
